Literature DB >> 6164436

Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.

S H Buck, T F Burks, M R Brown, H I Yamamura.   

Abstract

Substance P (SP) levels were determined by radioimmunoassay (RIA) in several regions of post-mortem brain of controls and Huntington's disease (HD) patients. In controls, highest SP levels were found in basal ganglia, substantia nigra and hypothalamus. Nigral pars reticulata contained 3--4-fold higher levels than pars compacta. In HD, SP levels were reduced in all basal ganglia and substantia nigra. The reductions ranged from 48% in caudate nucleus to over 90% in nigral pars reticulata. There were no changes in SP levels in HD frontal cortex, thalamus or hypothalamus.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6164436     DOI： 10.1016/0006-8993(81)90171-2

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  11 in total

Review 1.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  Characteristics of substance P transport across the blood-brain barrier.

Authors:  Arvind K Chappa; Kenneth L Audus; Susan M Lunte
Journal:  Pharm Res       Date:  2006-06-01       Impact factor: 4.200

3.  Synaptic connections of substance P-immunoreactive nerve terminals in the substantia nigra of the rat. A correlated light- and electron-microscopic study.

Authors:  P Somogyi; J V Priestley; A C Cuello; A D Smith; J P Bolam
Journal:  Cell Tissue Res       Date:  1982       Impact factor: 5.249

Review 4.  Genetics and neuropathology of Huntington's disease.

Authors:  Anton Reiner; Ioannis Dragatsis; Paula Dietrich
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

5.  Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease.

Authors:  D F Emerich; M D Lindner; S R Winn; E Y Chen; B R Frydel; J H Kordower
Journal:  J Neurosci       Date:  1996-08-15       Impact factor: 6.167

6.  Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.

Authors:  Wen-Qi Zeng; Eiman Al-Yamani; James S Acierno; Susan Slaugenhaupt; Tammy Gillis; Marcy E MacDonald; Pinar T Ozand; James F Gusella
Journal:  Am J Hum Genet       Date:  2005-05-03       Impact factor: 11.025

7.  Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study.

Authors:  M Zech; B Bogerts
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.

Authors:  Anna Nilsson; Maria Fälth; Xiaoqun Zhang; Kim Kultima; Karl Sköld; Per Svenningsson; Per E Andrén
Journal:  Mol Cell Proteomics       Date:  2009-01-08       Impact factor: 5.911

Review 9.  Disrupted striatal neuron inputs and outputs in Huntington's disease.

Authors:  Anton Reiner; Yun-Ping Deng
Journal:  CNS Neurosci Ther       Date:  2018-04       Impact factor: 5.243

10.  Differential loss of striatal projection neurons in Huntington disease.

Authors:  A Reiner; R L Albin; K D Anderson; C J D'Amato; J B Penney; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.